NEW YORK and BOSTON, Sept. 12, 2017 -- Mizuho Americas will host a Biotechnology Conference on September 19th at the Langham Hotel in Boston. The event will feature opportunities for institutional investors to meet senior executives from neurology companies that are pioneering advancements in gene therapy, pharmaceuticals and diagnostics.
Salim Syed, Managing Director and Head of Biotechnology Research for Mizuho Americas, will moderate three panel discussions with renowned research doctors discussing companies developing advancements in multiple sclerosis treatments, migraine relief through calcitonin gene-related peptide therapies and scientific strides in the prevention and treatment of Alzheimer’s disease.
“It is a dynamic time of growth and discovery for many biotech companies,” said Matt DeSalvo, Head of Equities, Mizuho Americas. “We have assembled top executives at firms who are experts in this sector and are creating some of the most exciting breakthroughs of our time.”
Institutional investors and C-suite executives will gain valuable insight and better understand the drivers and influences that will shape the biotech industry. Attendees will have an opportunity to meet with senior executives of these biotech companies. For more information, please contact Mizuho Americas Corporate Access at [email protected].
The Biotechnology Conference is the latest in a series of investor conferences hosted by Mizuho Americas that have taken place this year. The inaugural Global Mizuho Investor Conference (MIC), NY was held in November 2016 and will take place this year on December 4-5, 2017. The conference brings Mizuho’s clients together with key decision-makers and executives across the energy, financials, healthcare, industrials, REITs, TMT, consumer and utilities sectors in a one-on-one setting.
About Mizuho Americas
Mizuho Americas is a leading financial institution comprising several legal entities, which together offer clients corporate and investment banking, financing, securities, treasury services, asset management, research and more. With professionals in offices throughout the US, Canada, Mexico, Brazil and Chile, Mizuho’s operations in the Americas connect a broad client base of major corporations, financial institutions and public sector groups to local markets and a vast global network. Learn more at www.mizuhoamericas.com.
Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE:MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services including private banking and venture capital through its subsidiaries. The group has over 900 offices and 56,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. At the end of 2016, its total assets were $1.8 trillion. Learn more about Mizuho Financial Group at https://www.mizuho-fg.com
For further inquiries, please contact:
Jim Gorman
Director, Media Relations, Mizuho Americas
+1 212 282 3867; [email protected]
P.J. Kinsella
Paragon Public Relations
+1 646 558 6226; [email protected]


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Italy Fines Apple €98.6 Million Over App Store Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 



